Panbela Therapeutics is a clinical-stage biopharmaceutical company developing drugs that target the polyamine metabolic pathway, a biological system that cancer cells and some autoimmune conditions rely on for growth and survival. Panbela has no approved products and no revenue. Its two lead candidates are ivospemin (SBP-101) and Flynpovi (eflornithine + sulindac). Ivospemin is a polyamine analogue being tested in combination with standard-of-care chemotherapy for metastatic pancreatic cancer in the ASPIRE trial, a 600-patient global Phase III study where the primary endpoint is overall survival. Flynpovi combines eflornithine, an inhibitor of polyamine synthesis, with sulindac, an NSAID, to suppress polyamine production from two directions simultaneously. Flynpovi is being evaluated in the NCI-funded PACES Phase III trial for prevention of adenoma and cancer recurrence in colorectal cancer survivors, with data expected in the second half of 2026, and is also being pursued for familial adenomatous polyposis, a rare inherited condition with no currently approved drug therapies. Eflornithine as a standalone agent is being explored across several additional indications, mostly in externally funded trials. Panbela funds operations through equity raises, grants, and milestone payments from a 2023 divestiture of its pediatric neuroblastoma program to US WorldMeds. The company plans to partner with a larger pharma company for commercialization if any product reaches approval. Panbela operates with only 8 employees and relies on CROs and third-party manufacturers to run its programs.